✦ LIBER ✦

Current and novel therapies for the treatment of nonalcoholic steatohepatitis

✍ Scribed by David van der Poorten; Jacob George

Publisher: Springer-Verlag
Year: 2007
Tongue: English
Weight: 249 KB
Volume: 1
Category: Article
ISSN: 1936-0533
DOI: 10.1007/s12072-007-9011-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A pilot study of pioglitazone treatment

A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis

✍ Kittichai Promrat; Glen Lutchman; Gabriel I. Uwaifo; Renee J. Freedman; Alejandr 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 146 KB 👁 2 views

Nonalcoholic steatohepatitis (NASH) is a common chronic liver disease for which there is no known effective therapy. A proportion of patients with NASH progress to advanced fibrosis and cirrhosis. NASH is considered one of the clinical features of the metabolic syndrome in which insulin resistance p

Ursodeoxycholic acid for treatment of no

Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial

✍ Keith D. Lindor; Kris V. Kowdley; E. Jenny Heathcote; M. Edwyn Harrison; Roberta 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB 👁 2 views

No effective medical therapy is available for all patients with nonalcoholic steatohepatitis (NASH). Ursodeoxycholic acid (UDCA) has been suggested to be of benefit based on open label clinical studies. We randomized 166 patients with liver biopsy-proven NASH to receive between 13 and 15 mg/kg/d of

The immunopathogenesis of alcoholic and

The immunopathogenesis of alcoholic and nonalcoholic steatohepatitis: two triggers for one disease?

✍ Luca Valenti; Anna Ludovica Fracanzani; Silvia Fargion 📂 Article 📅 2009 🏛 Springer-Verlag 🌐 English ⚖ 346 KB

On the mechanism of action of vitamin E

On the mechanism of action of vitamin E for nonalcoholic steatohepatitis

✍ Hong-Fang Ji; Liang Shen 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 632 KB

Shorter duration and lower dose of peginterferon alfa-2a therapy results in inferior HBeAg seroconversion rates compared with the duration and dose of 48 weeks and 180 lg: NEPTUNE study.

Improved nonalcoholic steatohepatitis af

Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone

✍ Brent A. Neuschwander-Tetri; Elizabeth M. Brunt; Kent R. Wehmeier; Dana Oliver; 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 963 KB

Insulin resistance (IR) commonly is associated with nonalcoholic steatohepatitis (NASH). To establish whether IR causes NASH, this study was undertaken to determine if improving IR would improve the histologic features that define NASH. Thirty adults with prior biopsy evidence of NASH were enrolled

Accuracy and reproducibility of transien

Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis

✍ Valerio Nobili; Francesco Vizzutti; Umberto Arena; Juan G. Abraldes; Fabio Marra 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 171 KB 👁 2 views

Transient elastography (TE) has received increasing attention as a means to evaluate disease progression in chronic liver disease patients. In this study, we assessed the value of TE for the prediction of fibrosis stage in a cohort of pediatric patients with nonalcoholic steatohepatitis. Furthermore